Quick Answer
Solid Biosciences Inc. reported Total Assets of $232.54 million for the year ending 2025.
- Solid Biosciences Inc. showed an increase of +23.3% in Total Assets from 2024 to 2025.
- This data is from Solid Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $189.24 million | Q2 2018: $171.47 million | Q3 2018: $156.81 million | Q1 2019: $120.23 million | Q2 2019: $96.30 million | Q3 2019: $130.93 million | Q1 2020: $73.96 million | Q2 2020: $57.96 million | Q3 2020: $40.52 million | Q1 2021: $285.28 million | Q2 2021: $265.86 million | Q3 2021: $248.99 million | Q1 2022: $207.56 million | Q2 2022: $208.50 million | Q3 2022: $184.47 million | Q1 2023: $229.59 million | Q2 2023: $204.72 million | Q3 2023: $184.73 million | Q1 2024: $248.69 million | Q2 2024: $230.98 million | Q3 2024: $211.83 million | Q1 2025: $343.90 million | Q2 2025: $308.29 million | Q3 2025: $273.91 million.
- Over the full 9 years of available data (2017 to 2025), Solid Biosciences Inc.'s Total Assets has grown by 205.2%.
- Historical annual values: Fiscal year 2025: $232.54 million | Fiscal year 2024: $188.66 million | Fiscal year 2023: $164.94 million | Fiscal year 2022: $260.25 million | Fiscal year 2021: $232.38 million | Fiscal year 2020: $171.17 million | Fiscal year 2019: $103.47 million | Fiscal year 2018: $139.60 million | Fiscal year 2017: $76.19 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: